A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).

Trial Details

NCT ID
NCT05818683
Phase
PHASE1
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Pasritamig
  • Cetrelimab
  • Cabazitaxel
  • Docetaxel
  • Apalutamide
  • Enzalutamide
Locations (sample)
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Brooklyn, Mississippi, United States|31.05629,-89.18617
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Mineola, New York, United States|40.74927,-73.64068

Key Eligibility Criteria

  • Part 1 A-G, 1I, 1J, and 1K (all combination treatments) and Parts 2B-C (cabazitaxel, docetaxel): Metastatic castration-resistant prostate cancer (m…
  • Measurable or evaluable disease, except for Part 2H
  • (a) Part 1A (cetrelimab) - Prior treatment for mCRPC with at least 1 prior androgen receptor pathway inhibitors (ARPI) (that is, abiraterone acetat…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →